Acute Myeloid Leukemia
Conditions
Brief summary
The investigators have recently demonstrated the strong impact in terms of survivals of Fms-like tyrosine kinase 3 ligand (FL) levels evaluated during intensive induction in acute myeloid leukemia (AML) patients. Indeed, three FL kinetic profiles were delineated: i) sustained increase of FL concentrations between day (D) 1 and D22 (FLI group, n=26, good-risk), ii) increase from D1 to D15, then decrease at D22 (FLD group, n=22, intermediate-risk) and iii) stagnation of low levels (\<1000 pg/mL, FLL group, n=14, high-risk). However, with longer follow-up, the investigators have observed that FLI and FLD shared similar outcomes while FLL sub-group kept a very bad prognostic. Because serum samples from this previous study (called the FLAM/FLAL study) had been frozen-stored, the investigators were able to conduct an ancillary study assessing the potential impact of the kinetics of 6 other cytokines: TNFalpha, stem-cell factor, IL-1beta, IL-6, IL-10 and granulocyte-monocyte colony-stimulating factor (GM-CSF).. Only Il-6 level at D22 (\< or \>15.5 pg/mL) was associated with outcome allowing to distinguish between higher and lower survivals within the combined FLI/FLD sub-group. A new prognostic risk-stratification can thus be proposed as follows: FLI/FLD with IL-6 \<15.5 pg/mL (favorable), FLI/FLD with IL-6 \>15.5 pg/mL (intermediate) and FLL (high-risk). The aim of this new FLAMVAL study is to validate prospectively in a larger and independent cohort this prognostic risk-stratification i.e. that kinetic profile of FLT3L plasma level from D1 to D22 and Il6 plasma level at day 22 during induction of AML patients are predictive of overall and disease free survivals. For that purpose, 201 newly diagnosed AML patients treated intensively in the 25 centres of the French Innovative Leukemia Organisation (FILO) will be included in the FLAMVAL study.
Interventions
OTHERNo intervention
No intervention
Sponsors
Nantes University Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>= 18 years old * Confirmed diagnosis of AML according to World Health Organization (WHO) 2016 classification (Arber et al., 2016) * Non previously treated AML (first-line therapy) * Patients eligible to standard 3+7 induction chemotherapy with a minimum of 3 days of daunorubicin at 45mg/m2/day or a minimum of 5 days of idarubicin at 8mg/m2/day and a minimum of 7 days of cytarabin at 100mg/m2/day * Patients receiving any "third drug" combined to the "3+7" scheme, i.e. lomustine, corticotherapy, elthrombopag, gemtuzumab-ozogamycin, any FLT3 inhibitors… are eligible * Patients receiving CPX-351 (Vyxeos ®) are eligible * Patients requiring leukapheresis are eligible * Signed informed consent
Exclusion criteria
* Patients diagnosed with Acute Promyelocytic Leukemia (AML-3) * Adults under guardianship, subjects under protection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Confirm that the combination of the kinetic profile of FLT3L plasma levels and the IL-6 plasma level at day22 during induction in AML patients is predictive of overall survival. | 2 years | time from day 1 of induction to the date of death or of last follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Confirm that the new FL/IL6 risk-model predicts leukemia free survival in first-line AML patients. | 2 years | Progression-free survival (PFS): time from day 1 of induction to refractory disease or relapse censored at the date of death or last follow-up |
| Compare the prognostic impact of the new FL/IL6 risk-model with the impact of other parameters known to predict outcome in AML | 2 years | Refractory status after induction |
| Study the impact of the new FL/IL6 risk-model in FLT3 ITD or TKD patients receiving or not FLT3 inhibitors | 2 years | cytokines plasma levels |
| Study Immune reconstitution during induction | 2 years | By flow cytometry |
Countries
France
Outcome results
None listed